Per Horn (via Nobiex IVS) now owns a part of VaccImmune IVS (formerly Locimune IVS)
11.06.2018: New owner is registered on VaccImmune IVS (formerly Locimune IVS).
Per Horn (via Nobiex IVS ) is per. 11.06.2018 registered as owner of 33-50% of VaccImmune IVS (ex Locimune IVS) . In addition to Per Horn (via Nobiex IVS ), Morten Albrechtsen (via WEXOTEC ApS ) is also registered as owner of the company with an ownership of 50-67%. Morten Albrechtsen is registered as CEO of the company, founded in 2018. The company's purpose is described in CVR as
The company's purpose is to develop and sell locally administered products for the treatment of cancer with immune therapy
VaccImmune IVS (formerly Locimune IVS) is registered in CVR with the owner of VaccImmune Europe IVS .
VaccImmune Europe IVS Ownership Change
11.07.2018: Changes in owner registration for VaccImmune Europe IVS.
Favored, Inc. is now registered as owner of VaccImmune Europe IVS with a 100% ownership interest. At the same time, VaccImmune IVS , previously owned by 100%, waives its ownership of CVR's registration.
At the head of the company, Managing Director Morten Albrechtsen is in charge . VaccImmune Europe IVS is registered in the following industry: 'research and experimental development in biotechnology' and was founded in 2018.
